Patents by Inventor Jean-Marc Barret

Jean-Marc Barret has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Assignees: GAMAMABS PHARMA, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITE DE MONTPELLIER, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Publication number: 20200148777
    Abstract: The present invention relates to a glyco-engineered Fc fragment-bearing compound for its use as an immunosuppression inhibitor in the treatment of a cancer-associated immunosuppression. The invention further relates to a pharmaceutical composition comprising at least this glyco-engineered Fc fragment-bearing compound.
    Type: Application
    Filed: May 29, 2018
    Publication date: May 14, 2020
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Houcine BOUGHERARA, Emmanuel DONNADIEU
  • Patent number: 10509035
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: December 17, 2019
    Assignee: GAMAMABS PHARMA SA
    Inventors: Olivier Dubreuil, Jean-Marc Barret, Jean-François Prost, Delphine Desigaud
  • Publication number: 20190367625
    Abstract: The present invention relates to a human AMHRII-binding agent for its use for preventing or treating a cancer selected in a group of cancers comprising colon cancer, liver cancer, hepatocellular carcinoma, testis cancer, thyroid cancer, gastric cancer, gastrointestinal cancer, bladder cancer, pancreatic cancer, head and neck cancer, kidney cancer, liposarcoma, pleuramesothelioma, melanoma, sarcoma, brain cancer, osteocarcinoma and leukemia.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Inventors: Jean-Marc BARRET, Jean-François PROST, Mehdi LAHMAR, Stéphane DEGOVE, Olivier DUBREUIL, André NICOLAS, Didier MESURE
  • Publication number: 20180155433
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Application
    Filed: May 2, 2016
    Publication date: June 7, 2018
    Inventors: Thierry CHARDÈS, Olivier DUBREUIL, André PELEGRIN, Christel LARBOURET, Jean-François PROST, Jean-Marc BARRET, Stéphane DEGOVE
  • Publication number: 20170035903
    Abstract: This invention relates to antibody drug conjugates (ADC), antibody conjugates (AC) and novel antibodies. Particularly, the ADC, AC and antibodies disclosed herein specifically bind to the human anti-Müllerian hormone type II receptor (AMHR-II) and can be used to treat and/or identify AMHR-II expressing cancers, such as prostate cancer, breast cancer and gynecologic cancers expressing AMHR-II, such as ovarian cancer, in particular metastatic ovarian cancer, serous cancer, hypernephroma, endometrioid, colloidal epithelium, prostate cancer, germ cell cancer, endometrial cancer, mixed Müllerian malignant tumor of the uterus, leiomyosarcoma, or endometrial stromal sarcoma.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 9, 2017
    Inventors: OLIVIER DUBREUIL, JEAN-MARC BARRET, JEAN-FRANÇOIS PROST, DELPHINE DESIGAUD
  • Patent number: 9403840
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: August 2, 2016
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20150368258
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Application
    Filed: September 1, 2015
    Publication date: December 24, 2015
    Applicant: PIERRE FABRE MEDICAMENT
    Inventors: Thierry IMBERT, Yves GUMINSKI, Jean-Marc BARRET, Anna KRUCZYNSKI
  • Patent number: 9216989
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: December 22, 2015
    Assignee: PIERRE FABRE MEDICAMENT
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Patent number: 8569011
    Abstract: The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumors in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R1 is one or more NO2 groups in position 4 or 6, or a SO2Ph, SO2NMe2, SO2NH2 or SO3H group; R2 is hydrogen, C1-6 alkyl, benzyl, a perfluoroalkyl group; the values of a, b, c range from 2 to 5 independently from each other and represent alkylene chains separating the amino groups, and the values of d and e can independently be 0 or 1.
    Type: Grant
    Filed: June 11, 2012
    Date of Patent: October 29, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Jean-Philippe Annereau, Jean-Marc Barret, Yves Guminski, Thierry Imbert
  • Patent number: 8492567
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: July 23, 2013
    Assignee: Pierre Fabre Medicament
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20120283281
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Inventors: Thierry IMBERT, Yves GUMINSKI, Jean-Marc BARRET, Anna KRUCZYNSKI
  • Patent number: 8288567
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamidc, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. Formula (1) wherein: —R represents hydrogen or C1-4alkyl, —A represents CO(CH2)n or CONH(CH2)n where n=2, 3, 4, or 5, —R1 and R2 are as described herein.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: October 16, 2012
    Assignee: Pierre Fabre Medicament
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20120252059
    Abstract: The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R1 is one or more NO2 groups in position 4 or 6, or a SO2Ph, SO2NMe2, SO2NH2 or SO3H group; R2 is hydrogen, C1-6 alkyl, benzyl, a perfluoroalkyl group; the values of a, b, c range from 2 to 5 independently from each other and represent alkylene chains separating the amino groups, and the values of d and e can independently be 0 or 1.
    Type: Application
    Filed: June 11, 2012
    Publication date: October 4, 2012
    Inventors: Jean-Philippe Annereau, Jean-Marc Barret, Yves Guminski, Thierry Imbert
  • Publication number: 20110172257
    Abstract: The present invention relates to new derivatives of epipodophyllotoxin 4-substituted with an optionally substituted (poly)aminoalkylaminoalkylamide, or alkyl-urea or alkyl-sulfonamide chain, a process for preparing them and their use as a medicine as an anticancer agent. Formula (1) wherein: —R represents hydrogen or C1-4alkyl, —A represents CO(CH2)n or CONH(CH2)n where n=2, 3, 4, or 5, —R1 and R2 are as described herein.
    Type: Application
    Filed: August 19, 2009
    Publication date: July 14, 2011
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20110053967
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Application
    Filed: November 10, 2010
    Publication date: March 3, 2011
    Inventors: Thierry IMBERT, Yves GUMINSKI, Jean-Marc BARRET, Anna KRUCZYNSKI
  • Patent number: 7846926
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Grant
    Filed: April 14, 2005
    Date of Patent: December 7, 2010
    Assignee: Pierre Fabre Medicament
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Publication number: 20100202975
    Abstract: The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R1 is one or more NO2 groups in position 4 or 6, or a SO2Ph, SO2NMe2, SO2NH2 or SO3H group; R2 is hydrogen, C1-6 alkyl, benzyl, a perfluoroalkyl group; the values of a, b, c range from 2 to 5 independently from each other and represent alkylene chains separating the amino groups, and the values of d and e can independently be 0 or 1.
    Type: Application
    Filed: July 28, 2008
    Publication date: August 12, 2010
    Applicant: Pierre Fabre Medicament
    Inventors: Jean-Philippe Annereau, Jean-Marc Barret, Yves Guminski, Thierry Imbert
  • Publication number: 20090170843
    Abstract: The present invention relates to novel podophyllotoxin derivatives substituted in the 4-position by a substituted (poly)aminoalkylaminoacetamide chain, to their process of preparation and to their use as medicament as anticancer agents.
    Type: Application
    Filed: April 14, 2005
    Publication date: July 2, 2009
    Inventors: Thierry Imbert, Yves Guminski, Jean-Marc Barret, Anna Kruczynski
  • Patent number: 6127377
    Abstract: The invention concerns novel halogenated derivatives of the vinblastine and vinorelbine family, corresponding to general formula (I) and their therapeutically acceptable salts. The invention also concerns the application of these compounds in therapy and their method of preparation. The invention further concerns a novel method for preparing vinflunine or 20',20'-difluoro-3',4'-dihydrovinorelbine, of formula (a).
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: October 3, 2000
    Assignee: Adir et Compagnie
    Inventors: Alain Duflos, Jacques Fahy, Valerie Thillaye du Boullay, Jean-Marc Barret, Bridget Hill